NCT Number: NCT00319813
General Practice Quality Assurance Project. Chronic Obstructive Pulmonary Disease (COPD) Diagnosis and Treatment
A Cross sectional observational Quality Assurance Project in General Practice to COPD Diagnosis and Treatment
Looking for future studies?
Notify MeKey information
Conditions
Age range
35 year and older
Sex eligibility
All sexes
Study type
Observational
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- COPD patients over 35 years of age
- More than two annual renewals with the following group of inhalation preparations: Anticholinergic, beta-2 antagonists, steroids or a combination of these
Exclusion criteria
- Asthma
Treatment and study plan
Primary outcomes
-
To optimise the diagnosis and treatment of COPD via a quality assurance project
Time frame: Up to 1.2 years
-
Increase the knowledge and use of diagnostic tools and treatment amongst PCPs
Time frame: Up to 1.2 years
-
To focus on implementation of national guidelines for diagnosis and treatment of COPD
Time frame: Up to 1.2 years
Sponsors and collaborators
Lead sponsor
Boehringer Ingelheim
Industry
Registry information
Official study title
General Practice Quality Assurance Project. COPD Diagnosis and Treatment
Important dates
- Study start
- 2006
- Primary completion
- 2007
- Study completion
- 2007
- First posted
- Apr 27, 2006
- Registry last updated
- Dec 7, 2023
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder
NCT07252908
Chronic Disease, Disease Attributes
Chongqing, Chognqing, China
View Trial DetailsGenerative AI for Medication Counselling and Adherence in Community Pharmacies
NCT07649577
Asthma, Bronchial Diseases
Amman, Jordan
View Trial DetailsA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK3862995B Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and European Ancestry
NCT06979518
Chronic Disease, Disease Attributes
Cypress, California, United States
View Trial DetailsDetecting Systemic Carbon Dioxide Levels With a Novel Biosensor
NCT06367686
Apnea, Chronic Disease
Tønsberg, Norway
View Trial Details